Welcome to our dedicated page for ABPRO HLDGS SEC filings (Ticker: ABP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abpro Holdings filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and warrants, emerging growth company status, and regulatory disclosures for its antibody therapeutics business. Form 8-K reports cover FDA IND submission and clearance disclosures for ABP-102/CT-P72, material agreements, Nasdaq listing-rule matters, and board and committee changes.
Registration statements describe securities offerings and capital structure, including common stock and warrants. Periodic-report notices and late-filing forms address annual reporting obligations, while material-event filings provide formal records of governance, financing, operating, and public-company compliance matters.
Abpro Holdings, Inc. reported a smaller net loss of $1,028 thousand for the quarter ended March 31, 2026, compared with $3,887 thousand a year earlier, as operating expenses fell sharply to $933 thousand from $2,958 thousand.
Cash rose to $5,398 thousand and total assets to $6,865 thousand, mainly from issuing 3,162,785 shares under its Standby Equity Purchase Agreement for gross proceeds of $7,264 thousand. Despite this, current liabilities of $9,117 thousand and a stockholders’ deficit of $2,252 thousand leave the company with negative equity.
Management states there is substantial doubt about Abpro’s ability to continue as a going concern within one year without additional financing. Its common stock was delisted from Nasdaq effective February 23, 2026 and now trades on the OTC Pink Limited market under “ABPO,” which may further hinder capital-raising efforts.
Abpro Holdings, Inc. is an early-stage biotechnology company developing next‑generation multispecific antibody drugs for cancer and eye diseases, built on its DiversImmune and TetraBi platforms. The company completed a reverse recapitalization with SPAC Atlantic Coastal Acquisition Corp. II in November 2024 and effected a 1‑for‑30 reverse stock split effective October 31, 2025.
Abpro’s lead oncology asset ABP‑102, partnered worldwide with Celltrion, received FDA clearance of its IND on January 6, 2026, enabling a Phase 1 trial in HER2‑positive solid tumors. Ophthalmology candidate ABP‑201 is licensed regionally to Abpro Bio, with additional T‑cell engager programs ABP‑110 and ABP‑150 in pre‑clinical development.
The business is highly capital constrained. Management discloses substantial doubt about its ability to continue as a going concern and relies on external financing. A $50 million Standby Equity Purchase Agreement with YA II PN, Ltd. funded approximately $1.0 million in 2025 and $6.7 million of net proceeds in early 2026, but became unavailable after Abpro’s common stock was delisted from Nasdaq on February 23, 2026 and moved to the OTC Pink Limited Market. As of June 30, 2025, non‑affiliate market value was about $9.3 million, and 5,896,048 common shares were outstanding as of March 30, 2026.
Abpro Holdings, Inc. reported that Nasdaq’s Hearings Panel has decided to delist its common stock and public warrants because the company did not meet the minimum equity requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026. Trading on Nasdaq is scheduled to be suspended at the open on February 23, 2026.
The company has 15 days from February 18, 2026 to request a review by the Nasdaq Listing and Hearing Review Council and expects to appeal. If no appeal is pursued or successful, Nasdaq is expected to file a Form 25 to delist and deregister the securities under Section 12(b).
After Nasdaq trading is suspended, Abpro expects its common stock and public warrants to be eligible for quotation on the OTC Pink Market under the symbols “ABP” and “ABPWW.” The company warns investors that OTC Pink trading may involve reduced information, lower liquidity, and greater price volatility, and it cannot assure that any broker-dealer will make a market in its securities.
Abpro Holdings, Inc. reported that Nasdaq has notified the company it is no longer in compliance with several board and committee independence listing rules following the recent resignations of two independent directors, creating additional bases for potential delisting from The Nasdaq Capital Market.
Nasdaq cited noncompliance with rules requiring a majority-independent board, a three-member independent audit committee, and a two-member independent compensation committee. Abpro must present its views to a Nasdaq Hearings Panel by February 12, 2026, and has a cure period for the compensation committee extending to certain future shareholder meeting dates.
On February 9, 2026, Abpro appointed M. Fatih Karatas and Mary Gunn as Class II directors and to the audit, compensation, and nominating and corporate governance committees, aiming to address the independence and composition deficiencies. The company notes there is no immediate impact on the listing of its common stock or warrants, but there is no assurance it will regain full compliance or that the Panel will grant continued listing.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have disclosed a passive ownership stake in Abpro Holdings Inc. They report beneficial ownership of 196,537 shares of Abpro common stock, representing 6.8% of the outstanding class, as of the event date of 12/31/2025.
All 196,537 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive authority. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Abpro.
Abpro Holdings, Inc. reported that two members of its Board of Directors, Anthony D. Eisenberg and Sooyoung Lee, have resigned from the board and all related committees. Both resignations were effective in late January 2026 and were explicitly stated as not arising from any disagreement with the company, its board, or its management on operations, policies, or practices.
Following these departures, the Board has begun a process to identify and appoint new qualified independent directors to fill the vacancies and to meet applicable Nasdaq Stock Market requirements within the time periods allowed by the Nasdaq Listing Rules.
Abpro Holdings, Inc. entered into an unsecured $147,000 loan agreement with its Chief Executive Officer and Chairman, Miles J.W. Suk, to pay the premium for its directors’ and officers’ liability insurance. The CEO will pay the insurer or broker directly, and the funds may be used only for that insurance cost.
The loan runs for nine months and can be repaid early without penalty. No interest is charged for the first three months after funding; after that, the outstanding principal bears interest at a variable rate equal to three-month Term SOFR plus 2.0% per year, with interest due at maturity or earlier repayment. The loan is unsecured and not guaranteed by any third party.
On January 16, 2026, director Ian McDonald resigned from Abpro’s board and all board committees, with the company stating his resignation was not due to any disagreement over operations, policies, or practices. The board appointed Dr. Byung-Hak Yoon as a Class I director to fill the vacancy, with a term ending at the 2028 annual meeting, and named him to the Audit, Compensation, and Nominating and Corporate Governance Committees. Dr. Yoon, age 51, brings extensive leadership experience in biotechnology and medical companies and will receive the company’s standard compensation for independent directors.
Abpro Holdings, Inc. reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, its lead multispecific antibody oncology program. The therapy is being co-developed with Celltrion, Inc., and this clearance allows clinical studies of the candidate to begin under the IND. The update was shared via a press release furnished under a Regulation FD disclosure.